Anosmia and hyposmia significantly affect patients’ quality of life and have many etiologies, including trauma, inflammatory conditions including chronic rhinosinusitis, neoplasm, and viral infections, such as rhinovirus and SARS-CoV-2.
Objective:
Our purpose was to establish whether a consensus exists regarding optimal management of olfactory dysfunction and to provide insight into the treatment of anosmia in the current climate of increased prevalence secondary to COVID-19. Thus, we aimed to systematically review the literature on the management of non-Chronic-rhinosinusitis- related anosmia/hyposmia.
Methods:
PubMed, EMBASE, and Cochrane databases were searched for articles published since January 1990 using terms combined with Medical Subject Headings (MeSH). We included articles evaluating management of anosmia and hyposmia written in the English language, with original data, a minimum of 3 months of follow-up except for COVID-related studies, at least 2 patients, and well-defined and measurable outcomes.
Results:
A total of 3013 unique titles were returned upon the initial search. Of these, 297 abstracts were examined, yielding 19 full texts meeting inclusion criteria (8 with level 1 evidence, 3 with level 2, 1 with level 3, and 7 with level 4). The studies included a total of 1522 subjects, with follow up ranging from 3 to 72 months, with an exception for COVID related studies. Endpoints were based on clinically significant improvements of olfactory functions as measured through validated smell tests. Treatments with the most robust data were intranasal corticosteroids and olfactory training.
Conclusion:
The literature on the treatment of anosmia and hyposmia includes randomized trials showing the efficacy of a few modalities. While further research is needed to expand therapeutic options for this debilitating condition, the current literature supports the use of olfactory training and topical corticosteroids.
MiwaTFurukawaMTsukataniTCostanzoRMDiNardoLJReiterER.Impact of olfactory impairment on quality of life and disability. Arch Otolaryngol Head Neck Surg. 2001;127(5):497-503.
2.
RollsET.Taste, olfactory and food texture reward processing in the brain and the control of appetite. Proc Nutr Soc. 2012;71(4):488-501.
3.
KohliPSolerZMNguyenSAMuusJSSchlosserRJ.The association between olfaction and depression: a systematic review. Chem Senses. 2016;41(6):479-486.
4.
BoesveldtSPostmaEMBoakD, et al. Anosmia-a clinical review. Chem Senses. 2017;42(7):513-523.
5.
CroyINordinSHummelT.Olfactory disorders and quality of life—an updated review. Chem Senses. 2014;39(3):185-194.
6.
SuzukiYYamamotoSUmegakiH, et al. Smell identification test as an indicator for cognitive impairment in Alzheimer’s disease. Int J Geriatr Psychiatry. 2004;19(8):727-733.
7.
RossGWPetrovitchHAbbottRD, et al. Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol. 2008;63(2):167-173.
8.
HummelTWhitcroftKLAndrewsP, et al. Position paper on olfactory dysfunction. Rhinol Suppl. 2017;54(26):1-30.
9.
SolerZMPatelZMTurnerJHHolbrookEH.A primer on viral-associated olfactory loss in the era of COVID-19. Int Forum Allergy Rhinol. 2020;10:814-820.
10.
VetterPVuDLL’HuillierAGSchiblerMKaiserLJacqueriozF.Clinical features of covid-19. BMJ. 2020;369:m1470.
11.
MoeinSTHashemianSMMansourafsharBKhorram-TousiATabarsiPDotyRL.Smell dysfunction: a biomarker for COVID-19. Int Forum Allergy Rhinol. 2020;10:944-950.
12.
TongJYWongAZhuDFastenbergJHThamT.The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2020;163:3-11.
13.
VairaLADeianaGFoisAG, et al. Objective evaluation of anosmia and ageusia in COVID-19 patients: single-center experience on 72 cases. Head Neck. 2020;42(6):1252-1258.
14.
HeidariFKarimiEFirouzifarM, et al. Anosmia as a prominent symptom of COVID-19 infection. Rhinology. 2020;58(3):302-303.
15.
MengXDengYDaiZMengZ.COVID-19 and anosmia: a review based on up-to-date knowledge. Am J Otolaryngol. 2020;41(5):102581.
16.
SaltagiAKSaltagiMZNagAK, et al. Diagnosis of anosmia and hyposmia: a systematic review. Allergy Rhinol. 2021;12:21526567211026568.
17.
MoherDLiberatiATetzlaffJAltmanDG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006-1012.
18.
DurieuxNVandenputSPasleauF.[OCEBM levels of evidence system]. Rev Med Liege. 2013;68(12):644-649.
19.
SterneJACSavovićJPageMJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
20.
SterneJAHernánMAReevesBC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
21.
DammMPikartLKReimannH, et al. Olfactory training is helpful in postinfectious olfactory loss: a randomized, controlled, multicenter study. Laryngoscope. 2014;124(4):826-831.
22.
PatelZMWiseSKDelGaudioJM.Randomized controlled trial demonstrating cost-effective method of olfactory training in clinical practice: Essential Oils at uncontrolled concentration. Laryngoscope Investig Otolaryngol. 2017;2(2):53-56.
23.
AltundagACayonuMKayabasogluG, et al. Modified olfactory training in patients with postinfectious olfactory loss. Laryngoscope. 2015;125(8):1763-1766.
24.
HummelTWhitcroftKLRueterGHaehnerA.Intranasal vitamin A is beneficial in post-infectious olfactory loss. Eur Arch Otorhinolaryngol. 2017;274(7):2819-2825.
25.
SaatciOAltundagADuzOAHummelT.Olfactory training ball improves adherence and olfactory outcomes in post-infectious olfactory dysfunction. Eur Arch Otorhinolaryngol. 2020;277(7):2125-2132.
26.
NguyenTPPatelZM.Budesonide irrigation with olfactory training improves outcomes compared with olfactory training alone in patients with olfactory loss. Int Forum Allergy Rhinol. 2018;8(9):977-981.
27.
BlomqvistEHLundbladLBergstedtHStjärneP.Placebo-controlled, randomized, double-blind study evaluating the efficacy of fluticasone propionate nasal spray for the treatment of patients with hyposmia/anosmia. Acta Otolaryngol. 2003;123(7):862-868.
28.
StennerMVentJHüttenbrinkKBHummelTDammM.Topical therapy in anosmia: relevance of steroid-responsiveness. Laryngoscope. 2008;118(9):1681-1686.
29.
SaussezSVairaLAChiesa-EstombaCM, et al. Short-term efficacy and safety of oral and nasal corticosteroids in COVID-19 patients with olfactory dysfunction: a European multicenter study. Pathogens. 2021;10(6):698.
30.
KasiriHRouhaniNSalehifarEGhazaeianMFallahS.Mometasone furoate nasal spray in the treatment of patients with COVID-19 olfactory dysfunction: a randomized, double blind clinical trial. Int Immunopharmacol. 2021;98:107871.
31.
VairaLAHopkinsCPetrocelliM, et al. Efficacy of corticosteroid therapy in the treatment of long-lasting olfactory disorders in COVID-19 patients. Rhinology. 2021;59(1):21-25.
32.
RedenJHertingBLillKKernRHummelT.Treatment of postinfectious olfactory disorders with minocycline: a double-blind, placebo-controlled study. Laryngoscope. 2011;121(3):679-682.
33.
HenkinRIHoseinSStatemanWAKnöppelABAbdelmeguidM.Improved smell function with increased nasal mucus sonic hedgehog in hyposmic patients after treatment with oral theophylline. Am J Otolaryngol. 2017;38(2):143-147.
34.
HenkinRIVelicuISchmidtL.An open-label controlled trial of theophylline for treatment of patients with hyposmia. Am J Med Sci. 2009;337(6):396-406.
35.
LevyLMHenkinRILinCSHutterASchellingerD.Increased brain activation in response to odors in patients with hyposmia after theophylline treatment demonstrated by fMRI. J Comput Assist Tomogr. 1998;22(5):760-770.
36.
HenkinRISchultzMMinnick-PoppeL.Intranasal theophylline treatment of hyposmia and hypogeusia: a pilot study. Arch Otolaryngol Head Neck Surg. 2012;138(11):1064-1070.
37.
HummelTHeilmannSHüttenbriukKB.Lipoic acid in the treatment of smell dysfunction following viral infection of the upper respiratory tract. Laryngoscope. 2002;112(11):2076-2080.
38.
DaiQPangZYuH.Recovery of olfactory function in postviral olfactory dysfunction patients after acupuncture treatment. Evid Based Complement Alternat Med. 2016;2016:4986034. 2016.
39.
MoonHSChonJYLeeSHJuYMSungCH.Long-term results of stellate ganglion block in patients with olfactory dysfunction. Korean J Pain. 2013;26(1):57-61.
40.
KrajewskaJKrajewskiWZubKZatońskiT.COVID-19 in otolaryngologist practice: a review of current knowledge. Eur Arch Otorhinolaryngol. 2020;277:1885-1897.
41.
BrinerHRJonesNSimmenD.Olfaction after endoscopic sinus surgery: long-term results. Rhinology. 2012;50(2):178-184.
42.
DanielidesVKatotomichelakisMBalatsourasD, et al. Improvement of olfaction after endoscopic sinus surgery in smokers and nonsmokers. Ann Otol Rhinol Laryngol. 2009;118(1):13-20.
43.
LevyJMMaceJCSansoniERSolerZMSmithTL.Longitudinal improvement and stability of olfactory function in the evaluation of surgical management for chronic rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(11):1188-1195.
44.
LitvackJRMaceJSmithTL.Does olfactory function improve after endoscopic sinus surgery?Otolaryngol Head Neck Surg. 2009;140(3):312-319.
45.
ZiXXZhiLLJinP, et al. Olfactory change pattern after endoscopic sinus surgery in chronic rhinosinusitis with olfactory dysfunction. J Coll Physicians Surg Pak. 2018;28(8):612-617.
46.
HarlessLLiangJ.Pharmacologic treatment for postviral olfactory dysfunction: a systematic review. Int Forum Allergy Rhinol. 2016;6(7):760-767.
47.
PekalaKChandraRKTurnerJH.Efficacy of olfactory training in patients with olfactory loss: a systematic review and meta-analysis. Int Forum Allergy Rhinol. 2016;6(3):299-307.
48.
RezaeianA.Effect of intranasal insulin on olfactory recovery in patients with hyposmia: A randomized clinical trial. Otolaryngol Head Neck Surg. 2018;158(6):1134-1139.
49.
SchöpfVKollndorferKPollakMMuellerCAFreiherrJ.Intranasal insulin influences the olfactory performance of patients with smell loss, dependent on the body mass index: a pilot study. Rhinology. 2015;53(4):371-378.
50.
MavrogeniPKanakopoulosAMaihoubSKrasznaiMSzirmaiA.Anosmia treatment by platelet rich plasma injection. Int Tinnitus J. 2017;20(2):102-105.
51.
JiangRSTwuCWLiangKL.Medical treatment of traumatic anosmia. Otolaryngol Head Neck Surg. 2015;152(5):954-958.
52.
AibaTSugiuraMMoriJ, et al. Effect of zinc sulfate on sensorineural olfactory disorder. Acta Otolaryngol Suppl. 1998;538:202-204.
53.
GudziolVHummelT.Effects of pentoxifylline on olfactory sensitivity: a postmarketing surveillance study. Arch Otolaryngol Head Neck Surg. 2009;135(3):291-295.
54.
Amr kamel khalilA. Investigating the Potential Role of Aerosolized All-trans Retinoic Acid for Treating COVID-19 Anosmia and Regaining Sense of Smell. 2021. clinicaltrialsgov.
55.
D’AscanioLVitelliFCingolaniCMaranzanoMBrennerMJDi StadioA.Randomized clinical trial “olfactory dysfunction after COVID-19: olfactory rehabilitation therapy vs. intervention treatment with Palmitoylethanolamide and Luteolin”: preliminary results. Eur Rev Med Pharmacol Sci. 2021;25(11):4156-4162.
56.
WhitcroftKLEzzatMCuevasMAndrewsPHummelT.The effect of intranasal sodium citrate on olfaction in post-infectious loss: results from a prospective, placebo-controlled trial in 49 patients. Clin Otolaryngol. 2017;42(3):557-563.
KanjanaumpornJAeumjaturapatSSnidvongsKSeresirikachornKChusakulS.Smell and taste dysfunction in patients with SARS-CoV-2 infection: a review of epidemiology, pathogenesis, prognosis, and treatment options. Asian Pac J Allergy Immunol. 2020;38(2):69-77.
